Status:
COMPLETED
Phase II Study of Biaxin, Revlimid, and Dexamethasone for Untreated Multiple Myeloma
Lead Sponsor:
Weill Medical College of Cornell University
Collaborating Sponsors:
Celgene Corporation
Conditions:
Multiple Myeloma
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
PRIMARY STUDY OBJECTIVES * To evaluate the efficacy of the combination of clarithromycin (Biaxin®), lenalidomide (Revlimid™), and dexamethasone (Decadron®) as an induction therapy for patients with n...
Eligibility Criteria
Inclusion
- Subject must voluntarily sign and understand written informed consent.
- Histologically confirmed Durie-Salomon stage II or III MM (see Appendix II). Stage I MM patients will be eligible if they display poor prognostic factors (ß2M \> or = 5.5 mg/L, plasma cell proliferation index \> or = 5%, albumin of less then 3.0, and unfavorable cytogenetics).
- Measurable disease as defined by \> 1.0 g/dL serum monoclonal protein, \>0.1 g/dL serum free light chains, \> 0.2 g/24 hrs urinary M-protein excretion, and/or measurable plasmacytoma(s).
- Age \> or = 18 years at the time of signing the informed consent form.
- Karnofsky performance status \> or = 70% (\>60% if due to bony involvement of myeloma (see Appendix V).
- No prior treatment or less than one full course of first-line therapy. Patients may be receiving adjuvant antiresorptive therapy (i.e., pamidronate or zoledronic acid) as routine care.
- If the patient is a woman of childbearing age, she must have a negative serum or urine pregnancy test within 7 days of starting study.
- Due to the unknown risk of teratogenic side effects, subjects (women and men) must agree to use effective contraception throughout the duration of the study and for at least 1 month after discontinuation of study drugs.
- Life expectancy \> 3 months
- Absolute neutrophil count (ANC)\> or = 1000 cells/mm3 (1.0 x 109/L)
- Platelets count \> or = 75,000/mm3 (75 x 109/L)
- Serum SGOT/AST \< 3.0 x upper limits of normal (ULN)
- Serum SGPT/ALT \< 3.0 x upper limits of normal (ULN)
- Serum creatinine \< 2.5 mg/dL (221 µmol/L)
- Serum total bilirubin \< 2.0 mg/dL (34 µmol/L)
Exclusion
- Patients with non-secretory MM (no measurable monoclonal protein, free light chains, and/or M-spike in blood or urine).
- Prior history of other malignancies (except for basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the cervix or breast) unless disease free for ³ 5 years.
- NYHA Class III or IV heart disease. History of active angina, congestive heart disease, or myocardial infarction within 6 months.
- Pregnant or lactating women are ineligible.
- Known HIV positivity
- Active viral or bacterial infections or any coexisting medical problem that would significantly increase the risks of this treatment program.
- Known hypersensitivity to dexamethasone, clarithromycin, lenalidomide, or thalidomide.
- Prior therapy for the treatment of MM
- History of thromboembolic event or other condition currently requiring anticoagulation with warfarin (Coumadin). Patients whose therapy is changed to heparin are eligible.
Key Trial Info
Start Date :
December 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 29 2020
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT00151203
Start Date
December 1 2004
End Date
September 29 2020
Last Update
May 27 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Weill Medical College of Cornell University
New York, New York, United States, 10021